Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Signs On To Market Labopharm's Once-Daily Tramadol

This article was originally published in The Pink Sheet Daily

Executive Summary

Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.

You may also be interested in...



Labopharm’s Painful FDA Experience Continues

Canadian firm receives second “approvable” for once-daily analgesic tramadol, may pursue dispute resolution filed in December.

Labopharm’s Painful FDA Experience Continues

Canadian firm receives second “approvable” for once-daily analgesic tramadol, may pursue dispute resolution filed in December.

Labopharm Once-Daily Tramadol Is “Approvable”

The Canadian firm may still have an opportunity to reach its end-of-2006 launch goal for the opioid analgesic.

Topics

UsernamePublicRestriction

Register

LL1134561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel